R&D Clinical Trials Round-Up – Jan to Feb 2026 Read how Jan-Feb '26 offered a revealing cross-section of how R&D is evolving across therapy areas.
R&D AI in clinical development & ‘white space’, with Andrew Mack... Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.
R&D Rare disease at an inflection point: Why the next wave will ... As rare disease becomes more competitive, information parity is disappearing.
R&D Net Treatment Benefit in rare disease trials: Aligning trial... Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.
R&D How innovative trial approaches are advancing rare disease r... Innovative trial designs that harness data augmentation, RWD, and the power of AI are enabling a new era of rare disease research.
R&D Agentic AI and the human element: Building trustworthy autom... The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
